Meeting
2023 ASCO Annual Meeting
Aggregated analysis of 1,000 patients with cancer to assess the benefits of integrated whole exome and whole transcriptome sequencing.
Authors
Konstantin Chernyshov
BostonGene, Waltham, MA
Konstantin Chernyshov , Anna Love , Viacheslav Senichkin , Georgy Sagaradze , Konstantin Rumyantsev , Vladimir Kushnarev , Ekaterina Postovalova , Nikita Kotlov , Anna Ogloblina , Alexander Bagaev , Nathan Fowler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Molecular Diagnostics and Imaging
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3076)
DOI
10.1200/JCO.2023.41.16_suppl.3076
Abstract #
3076
Poster Bd #
274
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Transcriptomic signatures of MSI-high metastatic colorectal cancer to predict efficacy of immune checkpoint inhibitors.
First Author: Claire Gallois
Poster
2023 ASCO Annual Meeting
Pan-cancer analysis of IDO1 transcriptome expression and its impact on outcome in patients treated with immune checkpoint inhibitors.
First Author: Yu Fujiwara
Poster
2023 ASCO Annual Meeting
Differential genomic and transcriptomic analysis of invasive lobular and ductal carcinomas.
First Author: Jason A Mouabbi
Poster
2023 ASCO Annual Meeting
Cancer of unknown primary with gastrointestinal profiles: A distinct CUP subset.
First Author: Aakash Tushar Shah